% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Junkuhn:300323,
author = {C. Junkuhn and P. Schiele and A. L. Walter and F. Hamm and
B. Obermayer and D. Busch and A. Stroux and M. Frick and O.
Penack and F. Damm$^*$ and J. Polansky and L. Bullinger$^*$
and A. Künkele and M. Frentsch and I.-K. Na},
title = {{P}rior chemotherapy deteriorates {T}-cell quality for
{CAR} {T}-cell therapy in {B}-cell non-{H}odgkin's
lymphoma.},
journal = {Journal for ImmunoTherapy of Cancer},
volume = {13},
number = {4},
issn = {2051-1426},
address = {London},
publisher = {BioMed Central},
reportid = {DKFZ-2025-00769},
pages = {e010709},
year = {2025},
abstract = {Chimeric antigen receptor (CAR) T-cell therapy depends on T
cells that are genetically modified to recognize and attack
cancer cells. Their effectiveness thus hinges on the
functionality of a patient's own T cells. Since CAR T-cell
therapy is currently only approved for advanced cancers
after at least one line of chemotherapy, we evaluated the
potential negative effects of prior exposure to chemotherapy
on T-cell functionality.We studied T cells of two B-cell
non-Hodgkin's lymphoma patient cohorts, one collected before
treatment (pre-therapy) and the other after one or more
(median 3) lines of chemotherapy (post-therapy). Leveraging
advanced multiparameter flow cytometry, single-cell RNA
sequencing (scRNA-seq), whole-genome DNA methylation arrays
and in vitro functionality testing of generated CAR T cells,
we compared patient samples in their suitability for
effective CAR T-cell therapy.We discovered significant
modifications in T-cell subsets and their transcriptional
profiles secondary to chemotherapy exposure. Our analysis
revealed a discernible shift towards phenotypically more
differentiated T cells and an upregulation of markers
indicative of T-cell exhaustion. Additionally, scRNA-seq and
DNA methylation analyses revealed gene expression and
epigenetic changes associated with diminished functionality
in post-therapy T cells. Cytotoxicity assays demonstrated
superior killing efficacy of CAR T cells derived from
treatment-naïve patients compared with those with
chemotherapy history.These findings corroborate that
employing T cells collected prior to frontline chemotherapy
could enhance the effectiveness of CAR T-cell therapy and
improve patient outcomes.},
keywords = {Humans / Immunotherapy, Adoptive: methods / T-Lymphocytes:
immunology / T-Lymphocytes: drug effects / Lymphoma, B-Cell:
therapy / Lymphoma, B-Cell: immunology / Lymphoma, B-Cell:
drug therapy / Receptors, Chimeric Antigen: metabolism / DNA
Methylation / Male / Female / Adoptive cell therapy - ACT
(Other) / Chimeric antigen receptor - CAR (Other) / Lymphoma
(Other) / Receptors, Chimeric Antigen (NLM Chemicals)},
cin = {BE01},
ddc = {610},
cid = {I:(DE-He78)BE01-20160331},
pnm = {899 - ohne Topic (POF4-899)},
pid = {G:(DE-HGF)POF4-899},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:40210237},
doi = {10.1136/jitc-2024-010709},
url = {https://inrepo02.dkfz.de/record/300323},
}